Contact this trialFirst, we need to learn more about you.
Protein-Protein Interaction Inhibitor
AO-252 for Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This trial tests a new drug, AO-252, for safety and effectiveness in patients with advanced or hard-to-treat cancers like TNBC, HGSOC, and endometrial cancer. Researchers will study how the drug works in the body and its potential to reduce tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.